ArticleAntimicrobial agents and chemotherapy2002
Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00388167 (PROCAS), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection
Who cites it
16 citing papers in PubMed, 51 citations in OpenAlex.
- Translation Inhibition by Rocaglamide A Enhances Susceptibility of Yeasts to Caspofungin.bioRxiv : the preprint server for biology · 2025Article
- Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections.Clinical medicine insights. Pediatrics · 2012Article
- Novel FKS mutations associated with echinocandin resistance in Candida species.Antimicrobial agents and chemotherapy · 2010Article
- Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.Paediatric drugs · 2009Review
- Anidulafungin: an evidence-based review of its use in invasive fungal infections.Core evidence · 2008Article
- Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin.Antimicrobial agents and chemotherapy · 2008Article
- Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.Infection and drug resistance · 2008Article
- Resistance to echinocandin-class antifungal drugs.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2007Review
- Comparison of echinocandin antifungals.Therapeutics and clinical risk management · 2007Article
- Control of the C. albicans cell wall damage response by transcriptional regulator Cas5.PLoS pathogens · 2006Article
- Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.Antimicrobial agents and chemotherapy · 2005Article
- Yapsins are a family of aspartyl proteases required for cell wall integrity in Saccharomyces cerevisiae.Eukaryotic cell · 2005Article
- Review
- Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae.Antimicrobial agents and chemotherapy · 2004Article
- Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus.Antimicrobial agents and chemotherapy · 2004Article
- New methods to assess susceptibilities of Aspergillus isolates to caspofungin.Journal of clinical microbiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Caspofungin inhibits the synthesis of 1, 3-beta-D-glucan, an essential cell wall target in fungi. Genetic studies in the model yeast Saccharomyces cerevisiae have shown that mutations in FKS1 and FKS2 genes result in caspofungin resistance. However, direct demonstration of the role of gene overexpression in caspofungin resistance has been lacking. We transformed wild-type S. cerevisiae with an S. cerevisiae URA3-based GAL1 cDNA library and selected transformants in glucose synthetic complete plates lacking uracil (glucose SC minus uracil plates). We then moved the transformants to galactose SC minus uracil plates containing caspofungin (1 microg/ml) and looked for caspofungin-resistant colonies. We retested the candidates (true positives were sensitive on glucose caspofungin and resistant on galactose caspofungin media, respectively). We identified 16 caspofungin-resistant candidates. Restriction analysis and hybridization confirmed that 15 of the 16 clones were identical. We sequenced one of the cDNA clones and found that it contained the cDNA for SBE2. SBE2 has been described in S. cerevisiae to encode a Golgi protein involved in the transport of cell wall components (B. Santos and M. Snyder, Mol. Biol. Cell, 11:435-452, 2000). The SBE2 cDNA plasmid conferred again galactose-dependent caspofungin resistance when transformed back into the wild-type S. cerevisiae. Finally, the SBE2 deletion mutant was hypersensitive to caspofungin. In conclusion, overexpression of Sbe2p under the regulated control of the GAL1 promoter results in caspofungin resistance in S. cerevisiae. This transport pathway may provide insight into the tolerance or lack of sensitivity to caspofungin of some pathogenic fungi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.